2-(3-(2-chlorophenoxy)propoxy)pyrido[2,3-d]pyrimidin-4(3H)-one

ID: ALA1224070

PubChem CID: 135899171

Max Phase: Preclinical

Molecular Formula: C16H14ClN3O3

Molecular Weight: 331.76

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  O=c1[nH]c(OCCCOc2ccccc2Cl)nc2ncccc12

Standard InChI:  InChI=1S/C16H14ClN3O3/c17-12-6-1-2-7-13(12)22-9-4-10-23-16-19-14-11(15(21)20-16)5-3-8-18-14/h1-3,5-8H,4,9-10H2,(H,18,19,20,21)

Standard InChI Key:  JAETYFQMGNCXCJ-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
   -4.7699  -10.7837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7711  -11.6115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0580  -12.0246    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0600  -10.3708    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3461  -10.7797    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3428  -11.6139    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6274  -12.0296    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9055  -11.6162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9042  -10.7820    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6247  -10.3658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6246   -9.5405    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1894  -12.0310    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4753  -11.6206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2363  -12.0354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9550  -11.6250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6665  -12.0398    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.3852  -11.6295    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0939  -12.0474    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8075  -11.6377    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8105  -10.8115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0935  -10.3968    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3831  -10.8091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0891  -12.8727    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
 10 11  2  0
  8 12  1  0
  2  3  1  0
 12 13  1  0
  3  6  2  0
 13 14  1  0
  1  2  2  0
 14 15  1  0
  5  4  2  0
 15 16  1  0
  4  1  1  0
 16 17  1  0
  5 10  1  0
 17 18  2  0
  6  7  1  0
 18 19  1  0
  7  8  2  0
 19 20  2  0
  8  9  1  0
 20 21  1  0
  9 10  1  0
 21 22  2  0
 22 17  1  0
  5  6  1  0
 18 23  1  0
M  END

Alternative Forms

  1. Parent:

    ALA1224070

    ---

Associated Targets(Human)

HCAR2 Tclin Hydroxycarboxylic acid receptor 2 (1903 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HCAR3 Tchem HM74 nicotinic acid GPCR (353 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver microsomes (16955 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Hcar2 Hydroxycarboxylic acid receptor 2 (55 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver microsomes (8692 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 331.76Molecular Weight (Monoisotopic): 331.0724AlogP: 2.82#Rotatable Bonds: 6
Polar Surface Area: 77.10Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 8.13CX Basic pKa: 0.54CX LogP: 3.04CX LogD: 2.98
Aromatic Rings: 3Heavy Atoms: 23QED Weighted: 0.70Np Likeness Score: -0.94

References

1. Peters JU, Kühne H, Dehmlow H, Grether U, Conte A, Hainzl D, Hertel C, Kratochwil NA, Otteneder M, Narquizian R, Panousis CG, Ricklin F, Röver S..  (2010)  Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity.,  20  (18): [PMID:20724150] [10.1016/j.bmcl.2010.07.108]
2. Wise, Alan A and 16 more authors.  2003-03-14  Molecular identification of high and low affinity receptors for nicotinic acid.  [PMID:12522134]
3. Taggart, Andrew K P AK and 17 more authors.  2005-07-22  (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.  [PMID:15929991]
4. Jung, Jae-Kyu JK and 11 more authors.  2007-04-05  Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.  [PMID:17358052]
5. Semple, Graeme G and 21 more authors.  2008-08-28  3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.  [PMID:18665582]
6. Tang, Hua H, Lu, Jenny Ying-Lin JY, Zheng, Xiaomu X, Yang, Yuhua Y and Reagan, Jeff D JD.  2008-10-31  The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.  [PMID:18722346]
7. Deng, Qiaolin Q and 13 more authors.  2008-09-15  Molecular modeling aided design of nicotinic acid receptor GPR109A agonists.  [PMID:18760600]
8. Boatman, P Douglas PD, Richman, Jeremy G JG and Semple, Graeme G.  2008-12-25  Nicotinic acid receptor agonists.  [PMID:18983141]
9. Ren, Ning N and 9 more authors.  2009-05  Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G).  [PMID:19136666]
10. Shen, Hong C HC and 23 more authors.  2010-03-25  Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.  [PMID:20184326]
11. van Veldhoven, J P D JP and 8 more authors.  2011-05-01  Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A).  [PMID:21167710]
12. Boatman, P Douglas PD and 26 more authors.  2012-04-26  (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans.  [PMID:22435740]
13. Qin, Jun J and 22 more authors.  2011-02-10  Discovery of a potent nicotinic Acid receptor agonist for the treatment of dyslipidemia.  [PMID:24900295]
14. Palani, Anandan A and 29 more authors.  2012-01-12  Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.  [PMID:24900372]
15. Sprecher, Dennis D and 6 more authors.  2015-06-05  Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist.  [PMID:25773497]
16. Singh, L Ravithej LR and 8 more authors.  2018-05-25  Discovery of coumarin-dihydroquinazolinone analogs as niacin receptor 1 agonist with in-vivo anti-obesity efficacy.  [PMID:29709786]

Source